View Document Preview and Link
Document Date: 2015-05-19 10:54:48 Open Document File Size: 191,30 KB Share Result on Facebook
City Shanghai / Osaka / Marlborough / Washington / DC / / Company AEs / Sumitomo Dainippon Pharma Group / Sunovion Pharmaceuticals Inc. / Pharmaceuticals Inc. / Sumitomo Dainippon Pharma Co. Ltd. / Corporate Communications Sunovion Pharmaceuticals Inc. / Founding / / Country Japan / United States / / / Event FDA Phase / / Facility Massachusetts General Hospital / Arch Gen Psychiatry / Bipolar Clinic / / IndustryTerm machinery / treatment of mania associated with bipolar disorder / healthcare / pharmaceutical / / MedicalCondition Major Depressive Disorder / dementia / seizures / coma / muscle spasms / nausea / hypersomnia / tremor / drowsiness / Neuroleptic malignant syndrome / restlessness / memory loss / illness / hypersomnolence / schizophrenia / bipolar depression / hyperglycemia / anxiety disorders / stroke / seizure disorder / mania / diabetes / fever / dystonia / depression / impotence / bipolar disorder / dehydration / akathisia / / MedicalTreatment adjunctive therapy / / Organization American Psychiatric Association / FDA / Massachusetts General Hospital in Boston / / Person Gary Sachs / Depressive Disorder / Arch Psychiatry / Antony Loebel / Patrick Gaffey / / / Position pharmacist / physician / Head / Officer / Director / Major / Executive Vice President and Chief / Director of the Bipolar Clinic and Research Program / / Product Patients / / ProvinceOrState Massachusetts / / Technology CGI / / URL www.fda.gov/medwatch / www.ds-pharma.com / www.LATUDA.com / www.sunovion.com / / SocialTag